Market Capitalization (Millions $) |
20 |
Shares
Outstanding (Millions) |
6 |
Employees |
34 |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-14 |
Cash Flow (TTM) (Millions $) |
1 |
Capital Exp. (TTM) (Millions $) |
0 |
Aprea Therapeutics Inc
Aprea Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel cancer treatments. The company is primarily engaged in the research and development of small molecule drugs that restore the tumor suppressor protein p53 to its normal function. p53 is a crucial protein involved in regulating cell division and preventing the formation of cancerous tumors.
Aprea Therapeutics' lead candidate is called APR-246, which has shown promising results in clinical trials for various types of cancers, including hematologic malignancies and solid tumors. APR-246 works by reactivating mutated or inactivated p53 to induce apoptosis, or programmed cell death, in cancer cells while sparing healthy cells.
The company also has other research programs focused on addressing different aspects of p53 biology through drug discovery efforts. Aprea Therapeutics aims to develop innovative therapies that can significantly impact the lives of patients with cancer and improve treatment options.
Founded in 2003 and headquartered in Boston, Massachusetts, Aprea Therapeutics has collaborations and partnerships with various academic institutions, as well as pharmaceutical and biotechnology companies. The company's advancements in p53 biology and the development of APR-246 have garnered significant attention in the field of oncology.
Company Address: 3805 Old Easton Road Doylestown 18902 PA
Company Phone Number: 463-9385 Stock Exchange / Ticker: NASDAQ APRE
|